

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: I/97272 US

In re the application of:

Arno N. VERMEULEN and Dominique G.J. CLERCX-BREED

Serial Number: to be assigned Group Art Unit: to be assigned

Filed: concurrently herewith Examiner: to be assigned

For: VACCINES

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

April 8, 1998

Sir:

Prior to the calculation of the fee in the above-identified application, please make the following amendments:

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, line 2, insert -- Field of the Invention --; and
line 4, insert -- Background of the Invention --.

Page 2, line 11, insert -- Summary of the Invention --.

Page 3, after line 27, insert

--

Brief Description of the Drawings

Figure 1 T-cell responses of PBL from *E. tenella* infected (day 8 p.i.) and control chickens against different hydrophilic fractions of *E. tenella* sporozoites, HPS or total sporozoite antigen (sporo). Fractions were tested at a concentration of 0.15 x their original volume. (A) Mean proliferative responses. (B) Mean MAF-activity by PBL supernatants. Vertical lines indicate standard errors of the mean (SEM). *Significantly different from the untreated group (*P<0.05, **P<0.005, ***P<0.0005).

Express Mail No,
EL041880468US

0005606 14099

4
2/1A
66
5-23-98

Figure 2 SDS-PAGE of the hydrophilic fractions of *E. tenella* sporozoites used for vaccination. Stained with silver. Each set covers 3 lanes with two-fold serial dilutions of the fraction.

Figure 3 Vaccine potential of the selected antigen fractions. PBL were taken 11 days after booster vaccination and stimulated with *E. tenella* sporozoite antigen. (A) Mean proliferative PBL responses (B). Mean MAF-activity by supernatants. (C) Mean cecal lesion score of vaccinated groups following *E. tenella* challenge infection. Vertical lines indicate SEM. *Significantly different from the untreated group (* $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$).

Figure 4 Dose-effect response of antigen fraction 3. PBL were taken 11 days after booster vaccination and stimulated with *E. tenella* sporozoite antigen. (A) Mean proliferative PBL responses (B). Mean MAF-activity by supernatants. (C) Mean cecal lesion score of vaccinated groups following *E. tenella* challenge infection. Vertical lines indicate SEM. *Significantly different from the untreated group (* $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$). --

Page 4, above line 1, insert -- Detailed Description of the Invention --.

Page 32, delete lines 19 - 25 in their entirety.

Please delete page 34 in its entirety.